These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32313566)

  • 1. The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine:
    Riedl JM; Posch F; Prager G; Eisterer W; Oehler L; Sliwa T; Wilthoner K; Petzer A; Pichler P; Hubmann E; Winder T; Burgstaller S; Korger M; Andel J; Greil R; Neumann HJ; Pecherstorfer M; Philipp-Abbrederis K; Djanani A; Gruenberger B; Laengle F; Wöll E; Gerger A
    Ther Adv Med Oncol; 2020; 12():1758835919900872. PubMed ID: 32313566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients.
    Wang H; Fang K; Zhang J; Jiang Y; Wang G; Zhang H; Chen T; Shi X; Li Y; Duan F; Liu J
    Int Urol Nephrol; 2017 Aug; 49(8):1391-1398. PubMed ID: 28550473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of De Ritis Ratio with Prognosis in Patients with Coronary Artery Disease and Aminotransferase Activity within and outside the Healthy Values of Reference Range.
    Ndrepepa G; Cassese S; Scalamogna M; Lahu S; Aytekin A; Xhepa E; Schunkert H; Kastrati A
    J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.
    Lee H; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
    BJU Int; 2017 Feb; 119(2):261-267. PubMed ID: 27226065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery.
    Lee H; Choi YH; Sung HH; Han DH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Lee HM; Choi HY
    Clin Genitourin Cancer; 2017 Jun; 15(3):e379-e385. PubMed ID: 27692696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [
    Ruhwedel T; Rogasch JMM; Huang K; Jann H; Schatka I; Furth C; Amthauer H; Wetz C
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study.
    Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
    Dis Markers; 2019; 2019():6702964. PubMed ID: 31534562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of De Ritis (AST/ALT), ALP/ALT, and AST/ALP ratios as prognostic factors in patients with acute ischemic stroke.
    Ahmadabad MA; Naeimi A; Keymoradzadeh A; Faghani S; Ahmadabad MA; Boroujeni NA; Mohammadpour H; Saberi A
    BMC Neurol; 2022 Dec; 22(1):450. PubMed ID: 36463106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AST/ALT (De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Cancer.
    Knittelfelder O; Delago D; Jakse G; Reinisch S; Partl R; Stranzl-Lawatsch H; Renner W; Langsenlehner T
    Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33228184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.
    Zong Y; Peng Z; Wang X; Lu M; Shen L; Zhou J
    Cancer Manag Res; 2020; 12():12657-12666. PubMed ID: 33328763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients.
    Zinellu A; Arru F; De Vito A; Sassu A; Valdes G; Scano V; Zinellu E; Perra R; Madeddu G; Carru C; Pirina P; Mangoni AA; Babudieri S; Fois AG
    Eur J Clin Invest; 2021 Jan; 51(1):e13427. PubMed ID: 33043447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma.
    Ikeda T; Ishihara H; Takagi T; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Kondo T; Tanabe K
    Clin Genitourin Cancer; 2020 Jun; 18(3):236-240.e1. PubMed ID: 31917171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated AST/ALT (De Ritis) Ratio is a Risk Factor of Drainage Volume after Aortic Arch Surgery.
    Yan W; Zhang Q; Wang T; Sun J; Qian X; Ji B
    Heart Surg Forum; 2023 Dec; 26(6):E755-E763. PubMed ID: 38178336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of De Ritis Ratio in predicting prognosis in testicular cancer.
    Guner E; Seker KG; Arikan Y; Huseynov C; Sam E; Ozdal OL
    Aktuelle Urol; 2020 Jun; 51(3):285-289. PubMed ID: 32135561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
    Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study.
    Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
    Clin Genitourin Cancer; 2017 Oct; 15(5):598-604. PubMed ID: 28495053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy.
    Nishikawa M; Miyake H; Fujisawa M
    Urol Oncol; 2016 Sep; 34(9):417.e9-417.e15. PubMed ID: 27180325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De-Ritis Ratio Improves Long-Term Risk Prediction after Acute Myocardial Infarction.
    Steininger M; Winter MP; Reiberger T; Koller L; El-Hamid F; Forster S; Schnaubelt S; Hengstenberg C; Distelmaier K; Goliasch G; Wojta J; Toma A; Niessner A; Sulzgruber P
    J Clin Med; 2018 Nov; 7(12):. PubMed ID: 30477196
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
    Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy.
    Gorgel SN; Kose O; Koc EM; Ates E; Akin Y; Yilmaz Y
    Int Urol Nephrol; 2017 Sep; 49(9):1577-1583. PubMed ID: 28669104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.